Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries

Abstract excerpt

BACKGROUND & AIMS: Observational studies have linked lipid-lowering drug targets pro-protein convertase subtilisin/kexin 9 (PCSK9) and HMG-CoA reductase (HMGCR) with adverse liver outcomes; however, liver disease incidence varies across diverse populations, and the long-term hepatic impact of these lipid-lowering drugs among non-white Europeans remains largely unknown. METHODS: We use single nucleotide...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetic Associations and Epidemiology
• Share to Lipoproteins and Cardiovascular Health
• Share to Liver Disease Diagnosis and Treatment